Meet with... the Office of Translational Research at NINDS/NIH
Meet with... the Office of Translational Research at NINDS/NIH
Janssen Research & Development LLC , 3210 Merryfield Row , San Diego , CA 92121
March 18, 2014 from 11:30 AM to 13:30 PM (PDT)
$10 - $35
Are you working on a technology with neurological applications? Are you seeking funding from the NIH? Then here is your chance to meet with representatives from the Office of Translational Research (OTR) at the National Institute of Neurological Disorders and Stroke (NINDS) for a one-on-one discussion of potential options.
On March 18, hear from Dr. Rajesh Ranganathan and Dr. Amir Tamiz on potential opportunities for licensing and/or partnership on current projects in their portfolio and non-dilutive funding opportunities. The OTR provides critical path funding (approximately $100M annually) and research resources for biotechnology companies and university researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). Dr. Rajesh Ranganathan and Dr. Amir Tamiz will also discuss tips on preparing a competitive application, proper stage of development, and other factors that their institute is looking for when reviewing applications.
Following the presentation and Q&A, don't miss this opportunity to introduce yourself to the OTR at NINDS/NIH during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Dr. Rajesh Ranganathan and/or Dr. Amir Tamiz will provide a forum to further discuss your company with them.
Don't miss the opportunity to meet one-on-one with the Office of Translational Research at NINDS/NIH: apply today!
10:30am | Registration and Networking
11:00am | Presentation and Q&A
12:00pm | Networking Lunch
12:30-3:30pm | One-on-one Meetings*
*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends March 7th. APPLY HERE
Office of Translational Research at NINDS/NIH Participating Representatives:
Dr. Rajesh Ranganathan | Director of the Office of Translational Research (OTR), National Institutes for Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) read bio»
Dr. Amir Tamiz | Program Manager in the Office of Translational Research (OTR), National Institutes for Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) read bio»
About the Office of Translational Research at NINDS/NIH:
The Office of Translational Research (OTR) at the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), facilitates the preclinical discovery and development of new therapeutic interventions for neurological disorders. The OTR is comprised of 5 programs which help support the design, implementation, and management of research infrastructure activities that apply advanced research technologies to problems in neuroscience and neurology. The programs include: 1) the Anticonvulsant Screening Program (ASP), 2) Blueprint Network (BPN), 3) The Countermeasures Against Chemical Threats Program (CA), 4) Cooperative Agreement Program (CAP), and 5) The Small Business Innovative Research Program (SBIR).
The Anticonvulsant Screening Program (ASP) is a free screening service that facilitates the discovery and optimization of new therapeutic agents for the treatment of seizure and related disorders. Since 1974, ASP has made contributions to more than 10 AEDs currently on the market. The Blueprint Network (BPN) is a framework to enhance cooperative activities among 16 NIH Institutes and Centers, leveraging their resources to develop drugs from medicinal chemistry optimization through Phase I clinical testing and to facilitate industry partnerships for subsequent development of the drugs. The Countermeasures Against Chemical Threats Program (CA) in collaboration with the DOD is aimed at the discovery and/or identification of better therapeutic medical countermeasures and/or diagnostic technologies against chemical threat agents, which not only pose as terrorist threat agents, but also may be released during industrial (transportation/storage) accidents or natural disasters. The Cooperative Agreement Program (CAP) is a milestone-driven therapy discovery program (small molecules, biologics, stem cells, gene therapy and devices),-which as of 2012 had 42 projects with 8 filed INDs in 5 disease areas. The Small Business Innovative Research Program (SBIR) is a congressionally-mandated program intended to stimulate a partnership of ideas and technologies in the private sector and strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs. It supports innovative ideas at different stages of development, including applied bench research, translational research, and early stage clinical trials by funding the development of drugs, devices and biologics.
Presentation & Lunch Only
$25 | General Public
No onsite registration - event is full!
Includes presentation, Q&A, and lunch. Registration to attend the presentation, Q&A, and lunch will remain open until March 17th.
It is free to apply, but upon acceptance the following fees will apply:
$25 | Accepted Companies
Includes one-on-one meeting only. Companies must have applied for a one-on-one meeting ahead of time. The application period ends on March 7th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Dr. Rajesh Ranganathan | Director of the Office of Translational Research (OTR), National Institutes for Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Dr. Rajesh Ranganathan is currently the Director of the Office of Translational Research (OTR) at National Institutes for Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) and has been in this role since Jan. 2012. The OTR currently has five funding programs that aim to provide a breadth of opportunities for academic investigators and small businesses to engage in the spectrum of work, beginning with assay development through to initial test of clinical candidate in human trials. The emerging priorities of the office are to ensure that therapeutic development is partnered with the development of mechanistic biomarkers to facilitate deeper understanding of the mechanism of action of the therapeutic candidate. Additionally, there will be emphasis going forward on engaging other stakeholders, such as pharma, biotech, venture capital, and patient organizations to ensure that projects in the office's portfolio have been appropriately de-risked to ensure downstream investments, which will accelerate getting the much-needed therapies to patients suffering from neurological disorders.
Previously, Dr. Ranganathan served in the NIH Office of the Director beginning in Nov. 2010 as the Senior Advisor to the NIH Director for Translational Medicine, where he led efforts to assess the translational medicine pipeline across the NIH and helped formulate an NIH-wide strategy which culminated in the formation of the new NIH National Center for Advancing Translational Sciences (NCATS). Prior to that, spent 7+ years at the Novartis Institutes for BioMedical Research Inc. where he was a Director in the scientific strategy and portfolio management group and also founded and led a Global Office of Scientific Education for the Institutes. Dr. Ranganathan received his Bachelor's Degrees in Biology and Chemistry from Amherst College, performed his doctoral training with Dr. H. Robert Horvitz at MIT in C. elegans neurobiology, and his postdoctoral training with Dr. Linda Buck at Harvard Medical School and the Fred. Hutchinson Cancer Research Center in the area of mammalian sensory regulation.
Dr. Amir Tamiz | Program Manager in the Office of Translational Research (OTR), National Institutes for Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Dr. Amir Tamiz is currently a Program Manager in the Office of Translational Research (OTR) at National Institutes for Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) and has been in this role since Dec. 2012. Prior to joining National Institute of Health, Dr. Tamiz had held scientific and management positions in research and development of therapeutic programs at Corvas International (acquired by Dendreon), CovX (Pfizer), and Alba Therapeutics (Cephalon). His background includes leading multidisciplinary drug discovery and development teams, analytical method development, formulation, and manufacturing. Dr. Tamiz has a successful track record of transforming science and technologies into a number of clinically viable products in several therapeutic areas. Dr. Tamiz received his Ph.D. at University of Oregon and conducted postdoctoral research at the Department of Neuroscience - Georgetown University Medical center. At Oregon, he studied the design and synthesis of N-Methyl-D-aspartic acid inhibitors for the treatment of neurological disorders. Dr. Tamiz has more than 50 publications and patents.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by Janssen Labs is to help start-up entrepreneurs as well as the academic community connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include: Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund and Thomas McNerney & Partners.